Scholarlink

Purpose <p>Current risk stratification systems for prostate cancer (PCa) lack precision, particularly for intermediate-risk patients. PTEN loss has emerged as a promising biomarker for predicting aggressive disease. This study aims to evaluate the prognostic value of PTEN status in patients diagnosed via magnetic resonance imaging (MRI)-targeted biopsy and treated with radical prostatectomy (RP).</p> Methods <p>A retrospective analysis was conducted on a cohort of 213 patients diagnosed via MRI-targeted biopsy with available PTEN testing between 2020 and 2023 at a referral center. Patients who underwent RP with undetectable postoperative PSA levels and a minimum follow-up of three months were included. The primary outcome was the prognostic value of PTEN status. Biochemical recurrence (BCR) after RP was analyzed using Kaplan-Meier analysis and the log-rank test, while Cox regression models identified predictors of BCR.</p> Results <p>Overall, 36/213 (17%) patients exhibited PTEN loss. These patients had more aggressive disease, characterized by higher clinical stage and ISUP grade group (<i>p</i> ≤ 0.01). Among the 56 patients treated with RP and followed for a median of 25 months, BCR-free survival was significantly lower in those with PTEN loss, especially in the intermediate-risk subgroup (log-rank test, <i>p</i> = 0.03). PTEN loss was identified as an independent predictor of BCR (Hazard Ratio: 8.5, <i>p</i> = 0.03).</p> Conclusion <p>PTEN loss in patients diagnosed via MRI-targeted biopsy and treated with RP is associated with worse prognosis. PTEN testing shows promise as a biomarker to improve patient counseling and guide PCa treatment decisions. Prospective studies with longer follow-up periods are needed to validate these findings fully.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The prognostic value of PTEN expression in localized prostate cancer

  • 期刊论文

  • 发表日期：

    2025年8月25日

查看全文
  • Ayoub Bellouti,
  • Nicolas Sirtaine,
  • Thierry Roumeguere,
  • Alexandre Peltier,
  • Romain Diamand

摘要

Purpose

Current risk stratification systems for prostate cancer (PCa) lack precision, particularly for intermediate-risk patients. PTEN loss has emerged as a promising biomarker for predicting aggressive disease. This study aims to evaluate the prognostic value of PTEN status in patients diagnosed via magnetic resonance imaging (MRI)-targeted biopsy and treated with radical prostatectomy (RP).

Methods

A retrospective analysis was conducted on a cohort of 213 patients diagnosed via MRI-targeted biopsy with available PTEN testing between 2020 and 2023 at a referral center. Patients who underwent RP with undetectable postoperative PSA levels and a minimum follow-up of three months were included. The primary outcome was the prognostic value of PTEN status. Biochemical recurrence (BCR) after RP was analyzed using Kaplan-Meier analysis and the log-rank test, while Cox regression models identified predictors of BCR.

Results

Overall, 36/213 (17%) patients exhibited PTEN loss. These patients had more aggressive disease, characterized by higher clinical stage and ISUP grade group (p ≤ 0.01). Among the 56 patients treated with RP and followed for a median of 25 months, BCR-free survival was significantly lower in those with PTEN loss, especially in the intermediate-risk subgroup (log-rank test, p = 0.03). PTEN loss was identified as an independent predictor of BCR (Hazard Ratio: 8.5, p = 0.03).

Conclusion

PTEN loss in patients diagnosed via MRI-targeted biopsy and treated with RP is associated with worse prognosis. PTEN testing shows promise as a biomarker to improve patient counseling and guide PCa treatment decisions. Prospective studies with longer follow-up periods are needed to validate these findings fully.